Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Fortschr Neurol Psychiatr ; 79(1): 46-50, 2011 Jan.
Article in German | MEDLINE | ID: mdl-21161874

ABSTRACT

Dyskalemic paralyses are characterised by single or periodic episodes with muscle weakness that affect mostly the proximal skeletal muscles. Symptoms may last for a few hours or persist for several days, spontaneous recovery is common. Familial cases can be distinguished from secondary, non-familial forms which are based on other diseases, for example, of the thyroid gland, kidneys or gastrointestinal tract. Familial cases are mostly inherited in an autosomal-dominant pattern and belong to the channelopathies. Both groups are characterised by changed potassium levels in the blood during an episode. A detailed and accurate medical history (plus family history, use of medication and eating habits) often easily leads to the diagnosis. Provoking tests or instrumental and histological investigations can help to solve difficult cases. Treatment focuses on relieving acute symptoms and attacks can be managed by correcting the blood potassium to a normal level. Changing eating and/or exercise habits and also permanent medical treatment helps to prevent further attacks.


Subject(s)
Adrenocortical Adenoma/chemically induced , Diuretics , Glycyrrhiza , Hypokalemic Periodic Paralysis/chemically induced , Substance-Related Disorders/complications , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/therapy , Diagnosis, Differential , Humans , Hypokalemic Periodic Paralysis/diagnosis , Hypokalemic Periodic Paralysis/therapy , Male , Middle Aged , Muscle Weakness/chemically induced , Nervous System Diseases/chemically induced , Nervous System Diseases/physiopathology , Potassium/blood , Prognosis , Substance-Related Disorders/diagnosis , Substance-Related Disorders/therapy
2.
Clin Exp Allergy ; 39(8): 1246-54, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19438585

ABSTRACT

INTRODUCTION: The most widely used protocol for the induction of experimental allergic airway inflammation in mice involves sensitization by intraperitoneal (i.p.) injections of the antigen ovalbumin (OVA) used in conjunction with the adjuvant aluminium hydroxide (alum). Although adjuvants are frequently used, there are questions regarding the necessity of alum for murine asthma studies due to the non-physiological nature of this chemical. OBJECTIVE: The objective of this study was to compare experimental asthma phenotypes between adjuvant and adjuvant-free protocols of murine allergic airway inflammation in an attempt to develop a standardized alternative to adjuvant use. METHOD: An adjuvant-free OVA model of experimental asthma was investigated in BALB/c mice using i.p. or subcutaneous (s.c.) sensitization routes. For the s.c. sensitization, beta-galactosidase (beta-gal) was also tested as an antigen. In addition, OVA adjuvant and adjuvant-free sensitization protocols were compared in BALB/c and C57BL/6 mice. Open-field testing was performed to assess the effect of alum on mouse behaviour. RESULTS: Comparison of adjuvant vs. adjuvant-free and i.p. vs. s.c. protocols revealed that both adjuvant use and route of antigen application significantly influenced OVA-specific antibody production. Comparison of adjuvant and adjuvant-free protocols in this study clearly demonstrated the non-requirement of alum for the induction of acute allergic airway inflammation, as both protocols induce a similar disease phenotype. BALB/c mice were significantly more susceptible than C57BL/6 mice to sensitization. Using the improved s.c. adjuvant-free protocol, it was demonstrated that alternative antigens such as beta-gal can also be utilized. Behavioural studies indicated severe distress in mice treated with alum. CONCLUSION: The OVA s.c. adjuvant-free protocol used in this study generates a phenotype comparable to the benchmark adjuvant protocol widely used in the literature. The adjuvant-free alternative avoids the added complication of non-physiological adjuvants that may interfere with asthma treatment or prevention strategies.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Allergens/administration & dosage , Aluminum Hydroxide/administration & dosage , Asthma/physiopathology , Disease Models, Animal , Ovalbumin/administration & dosage , Adjuvants, Immunologic/chemistry , Aluminum Hydroxide/adverse effects , Aluminum Hydroxide/chemistry , Animals , Bronchial Hyperreactivity/physiopathology , Female , Injections, Intraperitoneal , Injections, Subcutaneous , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Phenotype , Sensitivity and Specificity , Skin Tests , beta-Galactosidase/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...